NCT02536859 - Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

April 14, 2016

Study Completion Date

April 14, 2016

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

insulin degludec

Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.

DRUG

insulin glargine

Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.

Trial Locations (1)

Novo Nordisk Investigational Site, Neuss